Therapy Market Research Reports & Industry Analysis

Defined as treatment of disabilities/illnesses (physical and mental), therapy represents an essential branch of medicine. This term is widely used by psychologists to describe the session between them and patients. Depending on an illness, different therapies types are applied. Therapies may be aimed at the prevention of the disease occurrence, stopping its further progress or preventing an outbreak. They may be also used to improve a patient’s comfort.

Therapies are classified on the basis of energy (e.g. phototherapy and thermotherapy), human interaction (for instance, psychotherapy and psychotherapy) and matter (e.g. gene therapy and biotherapy), etc.

The Catalogue is an unprecedented source of research reports analyzing the therapy market in detail. The reports uncover the market sizing and segmentation, its present standing and future prospects. The research studies investigate the competitive environment and contain majors’ profiles. Market igniters and limiters are scrutinized, and trends and future opportunities are unveiled in the reports.

Found 3791 publications
Global Pain Management Therapeutics Market Report 2016 US$ 2,850.00

2016 Global Pain Management Therapeutics Report is a professional and in-depth research report on the world's major regional market conditions of the Pain Management Therapeutics industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Pain Management Therapeutics industry; 3.) the North American Pain Management Therapeutics industry; 4.) the European Pain Management Therapeutics industry; 5.) market entry and investment feasibility; and ...

Aug, 2016 146 pages
Global Microbiome Therapeutics Market Report 2016 US$ 2,850.00

2016 Global Microbiome Therapeutics Report is a professional and in-depth research report on the world's major regional market conditions of the Microbiome Therapeutics industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Microbiome Therapeutics industry; 3.) the North American Microbiome Therapeutics industry; 4.) the European Microbiome Therapeutics industry; 5.) market entry and investment feasibility; and ...

Aug, 2016 146 pages
Global Liver Diseases Therapeutics Market Report 2016 US$ 2,850.00

2016 Global Liver Diseases Therapeutics Report is a professional and in-depth research report on the world's major regional market conditions of the Liver Diseases Therapeutics industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Liver Diseases Therapeutics industry; 3.) the North American Liver Diseases Therapeutics industry; 4.) the European Liver Diseases Therapeutics industry; 5.) market entry and investment feasibility; and ...

Aug, 2016 146 pages
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase... US$ 3,500.00

... for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) The report reviews High Affinity Nerve Growth Factor Receptor ...

Jul, 2016 106 pages
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016 US$ 3,500.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016 SUMMARY Global Markets Direct’s, ‘Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 ...

Jul, 2016 106 pages
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016 US$ 3,500.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016 SUMMARY Global Markets Direct’s, ‘Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 ...

Jul, 2016 110 pages
Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016 US$ 3,500.00

... Ang 2 or ANGPT2) - Pipeline Review, H2 2016 SUMMARY Global Markets Direct’s, ‘Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016’, provides in depth analysis on Angiopoietin 2 (Ang 2 or ANGPT2) targeted pipeline therapeutics. The report provides comprehensive information on the Angiopoietin 2 (Ang ...

Jul, 2016 63 pages
EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2025 US$ 3,995.00

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2025 Summary Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a ... procedure rates, as well as in the underlying demographic trends. Scope The Venous thromboembolism (VTE) EpiCast Report is an overview of the risk factors, comorbidities, and the global ...

Jul, 2016 69 pages
Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies US$ 4,995.00

Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies Summary Osteoporosis, the most common metabolic bone ...

Jul, 2016 131 pages
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs US$ 2,750.00

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs The report TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies ... ; Engineered TCR T-cells, including TCR target discovery; The current status of DLIs, CTLs and TILs; Manufacturing of T-cells for adoptive cell therapy; NK cells and CAR engineered NK cells; International perspective on TCR & CAR T-cell and NK cell ...

Jun, 2016 388 pages
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) The report reviews Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics under development ...

Jun, 2016 60 pages
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Pipeline Review, H1 2016 US$ 3,500.00

... Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a ...

Jun, 2016 39 pages
Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016 US$ 3,500.00

... Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016’, provides in depth analysis on Trans-Activator Of Transcription (Tat) targeted pipeline therapeutics. The report provides comprehensive information on the Trans-Activator Of Transcription (Tat), targeted therapeutics ...

Jun, 2016 43 pages
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016 US$ 3,500.00

... Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8), targeted therapeutics ...

Jul, 2016 74 pages
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) The report reviews Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted therapeutics under development ...

Jun, 2016 68 pages
TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016 US$ 3,500.00

... TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016’, provides in depth analysis on TAR DNA-Binding Protein 43 (TDP-43) targeted pipeline therapeutics. The report provides comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43), targeted therapeutics ...

Jun, 2016 46 pages
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2016 US$ 3,500.00

... Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) The report reviews Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics under development ...

Jun, 2016 46 pages
Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016 US$ 3,500.00

... Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) The report reviews Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics under development ...

Jun, 2016 52 pages
Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics under development ...

Jun, 2016 32 pages
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 US$ 3,500.00

... Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 SUMMARY Global Markets Direct’s, ‘Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics ...

Jun, 2016 49 pages
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016 US$ 3,500.00

... Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) The report reviews Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics under development ...

Jun, 2016 70 pages
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016 US$ 3,500.00

... CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016’, provides in depth analysis on CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted pipeline therapeutics. The report provides comprehensive information on the CaM Kinase (Ca2 ...

Jun, 2016 29 pages
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline... US$ 3,500.00

... for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine ...

Jun, 2016 100 pages
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor... US$ 3,500.00

Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H1 2016 ...

Jun, 2016 81 pages
Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016 US$ 3,500.00

... Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-Synuclein (alphaSyn or SNCA) targeted pipeline therapeutics. The report provides comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics ...

Jun, 2016 84 pages
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016 US$ 3,500.00

... Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted pipeline therapeutics ...

Jun, 2016 54 pages
Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Review, H1 2016 US$ 3,500.00

... Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) The report reviews Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics under development ...

Jun, 2016 53 pages
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016 US$ 3,500.00

... Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12 ...

Jun, 2016 62 pages
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development ...

Jun, 2016 31 pages
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016 US$ 3,500.00

... Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted pipeline therapeutics. The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV ...

Jun, 2016 121 pages
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) The report reviews Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development ...

Jun, 2016 61 pages
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) The report reviews Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics under development ...

Jun, 2016 72 pages
Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta or IKBKB or I-Kappa-B Kinase 2 or IKK2 or NFKBIKB or EC... US$ 3,500.00

... for Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta or IKBKB or I-Kappa-B Kinase 2 or IKK2 or NFKBIKB or EC 2.7.11.10) The report reviews Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear ...

Jun, 2016 39 pages
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016 US$ 3,500.00

... Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016’, provides in depth analysis on Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted pipeline ...

Jun, 2016 60 pages
Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 US$ 3,500.00

... Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016’, provides in depth analysis on Human Papilloma Virus (HPV) E7 Protein targeted pipeline therapeutics. The report provides comprehensive information on the Human Papilloma Virus (HPV) E7 Protein, targeted therapeutics ...

Jun, 2016 104 pages
HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016 US$ 3,500.00

HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016 SUMMARY Global Markets Direct’s, ‘HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016’, provides in depth analysis on HIV-1 Integrase (EC 2.7.7.) targeted pipeline therapeutics. The report provides comprehensive information on the HIV-1 Integrase ...

Jun, 2016 70 pages
Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016 US$ 3,500.00

... Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016 SUMMARY Global Markets Direct’s, ‘Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) - Pipeline Review, H1 2016’, provides in depth analysis on Glucokinase (Hexokinase-D or Hexokinase Type IV or EC 2.7.1.2) targeted pipeline therapeutics ...

Jun, 2016 56 pages
Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016 US$ 3,500.00

... Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016’, provides in depth analysis on Glial-Derived Neurotrophic Factor (GDNF) targeted pipeline therapeutics. The report provides comprehensive information on the Glial-Derived Neurotrophic Factor (GDNF), targeted therapeutics ...

Jun, 2016 46 pages
Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) The report reviews Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics under development ...

Jun, 2016 42 pages
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016 US$ 3,500.00

... Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) The report reviews E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP ...

Jun, 2016 64 pages
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Pipeline Review, H1 2016 US$ 3,500.00

... Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Pipeline Review, H1 2016’, provides in depth analysis on Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase ...

Jun, 2016 34 pages
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Pipeline Review, H1 2016 US$ 3,500.00

... ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) The report reviews Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) targeted therapeutics under development ...

Jun, 2016 39 pages
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 US$ 3,500.00

... -Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) The report reviews Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development ...

Jun, 2016 54 pages
Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) - Pipeline Review, H1 2016 US$ 3,500.00

... or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) The report reviews Carbonic Anhydrase 9 (Carbonate Dehydratase IX or CA-IX or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma-Associated Antigen G250 or EC 4.2.1.1) targeted therapeutics under development ...

Jun, 2016 41 pages
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016 US$ 3,500.00

... Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) The report reviews Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra ...

Jun, 2016 56 pages
Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology,... US$ 5,650.00

... following pointers: Market Penetration: Comprehensive information on product portfolios of top players in the plasma therapy market. The report analyzes the plasma therapy market on the basis of type, source, application ... in the plasma therapy market. Market Development: Comprehensive information about emerging markets; this report analyzes the market for various plasma therapy products across varied geographies. Market Diversification: Exhaustive ...

Jul, 2016 212 pages
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted therapeutics under development ...

Jun, 2016 60 pages
Global Systemic Psoriasis Therapeutics Market 2016-2020 US$ 2,500.00

... diagnosed with psoriasis is 41% if both parents have psoriasis, 14% in case one parent is affected, and 6% if a sibling has psoriasis. Technavio’s analysts forecast the global systemic psoriasis therapeutics market to grow at a CAGR ... of marketed drugs during the forecast period. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Systemic Psoriasis Therapeutics Market ...

Jul, 2016 88 pages
Stem Cell Therapy - Global Market Outlook (2015-2022) US$ 4,150.00

... to advancements in stem cell therapy and continuous R & D activities on stem cells. Whereas, Asia Pacific is likely to witness highest growth on account of favourable government policies, increasing adoption of stem cell therapy and rising population in China and India. Some of the key players in stem cell therapy market include Aastrom Biosciences ...

May, 2016 139 pages
Oxygen Therapy Market Analysis By Product (Oxygen Source Equipment, Cylinders, Concentrators, Liquid Oxygen Devices, PAP, Oxygen Delivery Device, Masks, Nasal Cannula, Venturi Mask, Non... US$ 4,700.00

... impact on the oxygen therapy market. These aforementioned factors are expected to serve as key contributing factors towards the growth of the oxygen therapy market over the forecast ... oxygen therapy set-ups, thereby contributing towards the overall oxygen therapy market growth during the forecast period. Oxygen concentrator spear headed the source equipment market ...

Apr, 2016 92 pages
1 2 3 4 5 >
Skip to top